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Abstract
Background: Scaffold Attachment Factor B1 (SAFB1) is a multifunctional protein which has been
implicated in breast cancer previously. We recently generated SAFB1 knockout mice (SAFB1-/-),
but pleiotropic phenotypes including high lethality, dwarfism associated with low IGF-I levels, and
infertility and subfertility in male and female mice, respectively, do not allow for straightforward
tumorigenesis studies in these mice. Therefore, we asked whether SAFB1 heterozygosity would
influence tumor development and progression in MMTV-Wnt-1 oncomice or DMBA induced
tumorigenicity, in a manner consistent with haploinsufficiency of the remaining allele.
Methods: We crossed female SAFB1+/- (C57B6/129) mice with male MMTV-Wnt-1 (C57B6/SJL)
mice to obtain SAFB1+/+/Wnt-1, SAFB1+/-/Wnt-1, and SAFB1+/- mice. For the chemical induced
tumorigenesis study we treated 8 weeks old SAFB1+/- and SAFB+/+ BALB/c mice with 1 mg DMBA
once per week for 6 weeks. Animals were monitored for tumor incidence and tumor growth.
Tumors were characterized by performing H&E, and by staining for markers of proliferation and
apoptosis.
Results: We did not detect significant differences in tumor incidence and growth between SAFB1+/
+/Wnt-1 and SAFB1+/-/Wnt-1 mice, and between DMBA-treated SAFB1+/+ and SAFB1+/-mice.
Histological evaluation of tumors showed that SAFB1 heterozygosity did not lead to changes in
proliferation or apoptosis. There were, however, significant differences in the distribution of tumor
histologies with an increase in papillary and cribriform tumors, and a decrease in squamous tumors
in the SAFB1+/-/Wnt-1 compared to the SAFB1+/+/Wnt-1 tumors. Of note, DMBA treatment
resulted in shortened survival of SAFB1+/- mice compared to their wildtype littermates, however
this trend did not reach statistical significance.
Conclusion: Our data show that SAFB1 heterozygosity does not influence Wnt-1 or DMBA-
induced mammary tumorigenesis.
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Background
Scaffold Attachment Factor B1 (SAFB1) is a multifunc-
tional protein that is involved in RNA processing, tran-
scriptional regulation, and stress response [1]. SAFB1 has
previously been implicated in breast tumorigenesis.
SAFB1 functions as an estrogen receptor α (ERα) corepres-
sor [2], and its overexpression in cultured cells leads to
growth inhibition. Importantly, SAFB1 mutations have
been identified in microdissected breast tumors but not in
the normal adjacent tissue, and SAFB1's chromosomal
locus displays extremely high loss of heterozygocity LOH
(78%) in invasive breast cancer [3]. There is no significant
different in LOH frequencies between ER-positive and ER-
negative tumors, and other in vitro observations [4] sug-
gest that SAFB1 could exert its effect on tumorigenesis, at
least in part, through ER-independent mechanisms. This
is further supported by our recent observation that loss of
SAFB1/SAFB1 is associated with worse overall survival of
breast cancer patients, but does affect Tamoxifen response
[5]. Collectively, these data suggest that SAFB1 loss affects
breast tumorigenesis in ER-dependent and independent
manner.
We have generated SAFB1 knockout (SAFB1-/-) mice [6]
which are characterized by high prenatal and neonatal
lethality, growth retardation associated with low serum
insulin-like growth factor I (IGF-I) levels, as well as female
subfertility and male infertility. The SAFB1-/- mice that are
born alive succumb to frailty, often associated with infec-
tions, and die of unknown reasons at an early age. These
pleiotropic phenotypes of SAFB1-/- mice make tumorigen-
esis studies difficult to perform, and we therefore asked
whether partial SAFB1 loss in SAFB1+/- mice would influ-
ence mammary tumor formation or progression. There-
fore, we used two different tumor models; transgenic
MMTV-Wnt-1 oncomice, and a chemical carcinogen
model, in which tumors were induced with 7, 12-dimeth-
ylbenz (a) anthracene (DMBA).
Genes of the Wnt family function in the regulation of
growth and differentiation of the mammary gland [7].
Mutation or deregulation of several components and tran-
scriptional targets of the Wnt signaling have been
observed in human cancers, including breast [8-12].
Mammary tumors induced by mouse mammary tumor
virus (MMTV) infection have revealed oncogenes
involved in murine mammary tumorigenesis [13], and
Wnt-1 was the first proto-oncogene discovered as a gene
frequently activated in mammary tumors arising in mice
infected with MMTV [14]. About 50% of MMTV-Wnt-1
transgenic female mice develop mammary tumors by 5–6
months of age [15], and these mice have therefore fre-
quently been used to study the effect of potential tumor
suppressor or oncogenes on mammary gland tumorigen-
esis (for review, see [16]).
DMBA is a prototypical polycyclic aromatic hydrocarbon
(PAHs) with carcinogenic and immunosuppressive effects
in various species [17]. Since it was first reported by Hug-
gins et al [18], DMBA-induced mammary tumors have
been widely used as a spontaneous cancer model in labo-
ratory animals including rats [19] and mice [20].
In this study, we have analyzed the effect of partial SAFB1
loss on Wnt-1 and DMBA-induced tumorigenesis. Here
show that SAFB1 heterozygosity does not affect tumor
incidence and tumor growth. However, we observed
changes in the Wnt-1 tumor histopathology, and a trend
towards shorter survival in DMBA-treated SAFB1+/- mice.
Results
SAFB1 protein expression is decreased in SAFB1+/- mice
First, we set out to confirm decreased SAFB1 protein levels
in SAFB1+/-  mice using a number of different tissues,
including testes, spleen, lung, and mammary gland (Fig-
ure 1A). Quantification revealed an average decrease of
42% in the SAFB1+/- mice, compared to SAFB1+/+ mice
(Figure 1B). A similar decrease was observed in the
tumors, where we detected an average of 53% decrease of
SAFB1 protein expression in SAFB1+/-/Wnt-1 tumors com-
pared to SAFB1+/+/Wnt-1 tumors (data not shown).
Tumor-free survival and tumor growth
SAFB1-Wnt-1 mice
We crossed female SAFB1+/- mice with male MMTV-Wnt-1
transgenic mice to obtain experimental mice. There was
no significant difference in time to tumor formation
between SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 in both
females (Figure 2A) and males (Figure 2B). The median
time to tumor formation (MTTF) was 31 weeks (n = 31)
for female SAFB1+/+/Wnt-1, and 34 weeks for female
SAFB1+/-/Wnt-1 mice (n = 29). Similarly, we did not detect
a significant difference in MTTF between SAFB1+/+/Wnt-1
(n = 23) and SAFB1+/-/Wnt-1 (n = 25) male mice. Thus,
partial SAFB1 loss does not accelerate the formation, or
alter the incidence of Wnt-1 induced mammary tumors.
Since tumor incidence was not significantly affected by
partial SAFB1 loss, we asked whether loss of one SAFB1
allele would result in accelerated rates of tumor growth, as
has been described for other models such as p21+/-/Wnt-1
[21]. We therefore analyzed length of time necessary for
tumors to grow from < 50 mm3 (time of detection by pal-
pation) to 1000 mm3. Tumors in female mice grew
slightly faster (Figure 2C) than in male mice (Figure 2D),
however, there was no significant difference between
SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 animals in either
group.
Since Wnt-1 mice can develop lung metastases [22], we
also asked whether partial loss of SAFB1 would affect theMolecular Cancer 2009, 8:15 http://www.molecular-cancer.com/content/8/1/15
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SAFB1 protein expression in tissues from SAFB1+/+ and SAFB1+/- mice Figure 1
SAFB1 protein expression in tissues from SAFB1+/+ and SAFB1+/- mice. A) A representative immunoblot using lysates 
from different tissues, and antibodies, as indicated. β-actin was used as a loading control. Blots are shown are from mice on a 
C57Bl/6J × 129/Sv genetic background, but is also representative of difference observed in mice on a BALB/c background. B) 
Percentage of SAFB1 protein levels in SAFB1+/- tissues, corrected for b-actin levels, relative to protein levels in SAFB1+/+ mice.
M
a
m
m
a
r
y
g
l
a
n
d
T
e
s
t
e
s
S
p
l
e
e
n
L
u
n
g
T
e
s
t
e
s
S
p
l
e
e
n
L
u
n
g
M
a
m
m
a
r
y
g
l
a
n
d
A)
SAFB1
ȕ-Actin
SAFB1+/+ SAFB1+/-
B)
0
20
40
60
80
100
120
S
A
F
B
1
 
l
e
v
e
l
s
 
(
%
 
o
f
 
+
/
+
)
0
20
40
60
80
100
120
0
20
40
60
80
100
120
Testes
Spleen
Lung
Mammary
glandMolecular Cancer 2009, 8:15 http://www.molecular-cancer.com/content/8/1/15
Page 4 of 11
(page number not for citation purposes)
Effect of SAFB1 heterozygosity on Wnt-1-induced tumorigenesis Figure 2
Effect of SAFB1 heterozygosity on Wnt-1-induced tumorigenesis. Kaplan-Meier survival curves of female (A) and 
male (B) SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 mice. Ages in weeks were recorded at the time of first tumor observation. C) 
and D) Growth rates of tumors in female and male Wnt-1 transgenic mice, respectively, on a SAFB1+/+ or SAFB1+/- back-
ground. The graphs represent time in weeks for tumor growth from detection to 1000 mm3, with error bars representing 
SEM.
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metastatic potential in our animals. We microscopically
analyzed H&E-stained lung tissue, and detected metas-
tases in 4 out of 13 SAFB1+/+/Wnt-1, and in 3 out of 8
SAFB1+/-/Wnt-1 mice which was not statistically different.
Thus, SAFB1 heterozygosity did not affect the develop-
ment of lung metastases in the Wnt-1 mice.
IGF-I plays an important role in cell proliferation, differ-
entiation, and apoptosis, and it has also been linked to
malignant transformation and breast cancer pathogenesis
[23-26]. Numerous studies have shown that a reduction
of circulating IGF-I is associated with a decrease in carcin-
ogen and oncogenes induced cancer (in particular, breast
and colon cancer) [27]. Interestingly, SAFB1-/- mice are
characterized by growth retardation, which was correlated
with low serum IGF-I levels [6]. However, we did not
detect a significant difference in IGF-I levels between
SAFB1+/+/Wnt-1 or SAFB1+/-/Wnt-1 mice (data not
shown), and can thus exclude the possibility that
decreased IGF-I levels could mask an effect of SAFB1 het-
erozygosity on tumorigenesis.
DMBA treatment
We next analyzed the effect of SAFB1 heterozygosity on
DMBA induced tumorigenesis in BALB/c mice. This study
comprised of 67 female mice (34 SAFB1+/+ and 33 SAFB1+/
-) in the treatment group, and 15 mice (8 SAFB1+/+ and 7
SAFB1+/-) in the vehicle treated control group.
We first analysed the development of mammary tumors
after DMBA treatment. Seventeen mice (28.4%) of the
DMBA treated animals developed mammary tumors,
however there was no significant difference in tumor
development between SAFB1+/+ (n = 9) and SAFB1+/- (n =
10) mice (Figure 3A).
In addition to the mammary gland tumors, animals also
developed tumors in other organs including skin, blood,
intestine, liver, and lung. A total of 34 animals (50.7%)
developed at least one tumor during the study period (17
SAFB1+/+ and 17 SAFB1+/-), but again there was no signifi-
cant difference in tumor free survival (from all tumors)
between SAFB1+/+ and SAFB1+/- mice (Figure 3B).
Next we analyzed the overall survival (OS) of the DMBA
treated animals. The data captured for OS included death
as a result of tumorigenesis, and sacrifice due to co-mor-
bidity of unknown reasons. Interestingly, there was a
trend for shorter OS in the SAFB1+/- mice; the median sur-
vival was 40 weeks for SAFB1+/+, and 35 weeks for SAFB1+/
- mice (Figure 3C). To investigate whether this could be
due to differential effects of DMBA on the hematopoietic
system, we performed complete blood count (CBC) and
blood smear test for 15 DMBA treated mice (7 SAFB1+/+
and 8 SAFB1+/-), and 2 control mice. Although one
SAFB1+/-  mice developed B-cell lymphoma, all other
blood parameters including red blood cell count, white
blood cell count, platelet count, amount of hemoglobin,
mean corpuscular volume, mean corpuscular hemo-
globin, and mean corpuscular hemoglobin concentration,
were not significantly different between both genotypes
(data not shown), suggesting that the observed trend was
unlikely due to a defect in hematopoietic system in the
SAFB1+/- mice. In summary, SAFB1 heterozygosity did not
lead to statistically significant effects on DMBA-induced
tumorigenesis.
Histological analysis of tumors
SAFB1-Wnt-1 tumor
We next asked whether partial SAFB1 loss would lead to
changes in the histopathology of the Wnt-1 tumors. H&E
staining revealed that tumors of both SAFB1 genotypes
were well-differentiated, and mainly characterized by
three tumor patterns: papillary, cribriform, and squamous
(Figure 4A). There was a small difference in the pattern
distribution between the two genotypes: while the papil-
lary, cribriform, and squamous pattern represented 45–
50%, 40–45%, and <5% distribution respectively, in
SAFB1+/+/Wnt-1 tumors, they represented 70%, 25% and
<5% distribution, respectively, in SAFB1+/-/Wnt-1 tumors
(p = 0.01).
Next, we set out to determine whether there was a differ-
ence in proliferation and apoptosis between SAFB1+/+/
Wnt-1 and SAFB1+/-/Wnt-1 tumors. Therefore, we stained
the tumors using BrdU antibody to detect the percentage
of cells in S phase, and using phosphorylated H3 (phos-
pho H3) antibody to detect mitotic cells. We did not
observe significant changes in the mitotic figures (Figure
4B), and in number of BrdU-positive cells between
SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 mice (data not
shown). Similarly, we did not detect a significant differ-
ence in rates of apoptosis, as measured by IHC using anti-
bodies for cleaved caspase 3, although there was a trend
towards decreased apoptosis in the SAFB1+/-/Wnt-1 mice
(p = 0.0742 as calculated by unpaired t test, n = 10 per
each genotype) (Figure 4C). Together, these data show
that partial SAFB1 loss does not affect proliferative and
apoptotic rates in Wnt-1 tumors.
DMBA induced tumors
Finally, we determined whether SAFB1 heterozygosity
would lead to changes in the histopathology of the
DMBA-induced mammary tumors. H&E staining revealed
similar histopathology in both groups, in that the tumors
mostly contained keratinized squamous epithelial cells
(Figure 5A). We also did not detect any significant differ-
ence in the percentage of BrdU-positive cells (data not
shown), and cleaved caspase-3 positive cells (Figure 5B)
between the two SAFB1 genotypes. We thus conclude thatMolecular Cancer 2009, 8:15 http://www.molecular-cancer.com/content/8/1/15
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Effect of SAFB1 heterozygosity on DMBA induced tumorigenesis Figure 3
Effect of SAFB1 heterozygosity on DMBA induced tumorigenesis. Kaplan-Meier survival curves of mammary gland 
tumor free (A), all tumor free (B), and overall survival (C) in DMBA-treated SAFB1+/+ and SAFB1+/- mice. Time in weeks were 
recorded from the first day of DMBA treatment to the time of first tumor observation (A, B), and death or sacrifice of animals 
due to comorbidity (C).
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Histological evaluation of Wnt-1 tumors of different SAFB1 genotype Figure 4
Histological evaluation of Wnt-1 tumors of different SAFB1 genotype. A) Both SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 
mice exhibit papillary, cribriform and squamous tumor type patterns. Representative pictures are shown (magnification 20×). 
B) Tumors found in the female (n = 10 per each genotype) mice were sectioned and stained with phospho H3 antibody. Rep-
resentative pictures are shown (magnification 40×). The graph represents the quantification of phospho H3-positive cells/field. 
Error bars represent SEM. C). Wnt-1 tumours found in the female mice were sectioned and stained with caspase 3 antibody (n 
= 10 per each genotype). Representative pictures are shown (magnification 40×). The graph shows quantification of caspase 3-
positive cells/field, with error bars representing SEM (p = 0.0742). Bars represent 100 μm.
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SAFB1 heterozygosity did not affect proliferative and
apoptotic rates in DMBA-induced tumors.
Discussion
To better understand SAFB1's role in tumorigenesis in
vivo, we have analyzed the effect of partial SAFB1 loss on
Wnt-1 and DMBA induced tumorigenesis. Our results
show that SAFB1 heterozygosity does not accelerate inci-
dence or growth of either Wnt-1 or DMBA-induced
tumors.
The absence of an effect could suggest that SAFB1 hetero-
zygosity is not sufficient to cause an increase in tumori-
genesis. Indeed, the classical Knudson's two-hit
hypothesis states that tumor suppressor genes are reces-
sive, and that both alleles must be inactivated for tumori-
genesis [28]. This model was based on the repeated
observation that familial cancers often result from the ini-
tial germline mutation of one allele of a tumor suppressor
gene, followed by subsequent somatic mutation or loss of
the second allele. Consistent with this, there are numer-
ous studies showing that loss of a single allele of a tumor
suppressor gene does not increase tumorigenesis. For
example, partial p53 loss did not accelerate Wnt-1 [29] or
DMBA-induced mammary tumorigenesis [30]. Similarly,
Brca1 and Brca2 heterozygosity did not affect tumor for-
mation induced by the Wnt-1 transgene [16], and partial
deletion of the INK4a locus that encodes both p16INK4a
and p19ARF did not result in increased DMBA-induced
tumor formation [31]. However, there are also many
reports where heterozygosity results in significantly
increased tumorigenicity, thus demonstrating haploinsuf-
ficiency of the remaining allele. For example, inactivation
of a single allele of the gene encoding the cyclin-depend-
ent kinase inhibitor p27Kip1 was sufficient to sensitize
mice to radiation and carcinogen-induced tumorigenesis
[32]. Dmp1-heterozygote mice treated with DMBA or ion-
izing radiation accelerated tumorigenesis compared to the
wild type [33]. Similarly, MMTV-Wnt-1 transgenic mice
which are heterozygous for PTEN developed mammary
tumors earlier than the PTEN wild type mice [22]. At this
point of time, we cannot exclude the possibility that par-
tial SAFB1 loss would influence the tumorigenicity in
other tumor models. For example, as discussed above,
partial p53 loss did not cooperate with Wnt-1 [29], how-
ever, it did accelerate tumor development in MMTV-Ras
[34] and MMTV-Myc [35] mice models.
Our study specifically addressed the question of the effect
of SAFB1 heterozygosity in hormone-independent mam-
mary gland tumors. Both, in vitro [4,36] and in vivo [5]
data suggest that SAFB1 has ER-independent activities.
Unpublished studies from our group showed that SAFB1
heterozygosity results in increased ER activity in MEFs,
both in the absence and presence of ligand, and thus
future studies should address potential effects of SAFB1
heterozygosity in development of hormone-dependent
tumors, such as the p53-/- tumors [37].
Two interesting observations from this study warrant fur-
ther discussion. First, we observed a non-significant trend
towards a shorter overall survival of SAFB1+/- mice com-
pared to the SAFB1+/+ mice after DMBA treatment. We did
not find any obvious defects in the haematopoietic system
but the increase in lethality could be due to increased
tumor development in other organs, or defects in the
immune system, resulting from the partial loss of SAFB1.
Second, we observed subtle differences in the histological
distribution pattern of the papillary and cribriform tumor
types between SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1
tumors. The Wnt pathway is known to influence cell fate
determination, stem cells renewal, and expansion of pro-
genitor cells in a number of tissues, including the mam-
mary gland [38-40]. Wnt1-ransformed progenitor cells
might differentiate into multiple cells types, resulting in
Histological evaluation of DMBA induced tumors of different  SAFB1 genotype Figure 5
Histological evaluation of DMBA induced tumors of 
different SAFB1 genotype. A) Both SAFB1+/+ and 
SAFB1+/- mice mostly exhibit squamous tumor type patterns. 
Representative pictures are shown (magnification 20×). B) 
DMBA-induced tumors were stained with cleaved caspase 3 
antibody. Representative pictures are shown (magnification 
40×). Bars represent 100 μm for A and 50 μm for B.
A) DMBA induced mammary tumours
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B) SAFB1+/+ SAFB1+/-
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tumor heterogeneity. A role of SAFB1 affects in this func-
tion of Wnt-1 could explain the altered histology of
tumors in SAFB1+/-/Wnt-1 tumors.
In summary, we have shown that partial SAFB1 loss does
not cooperate with Wnt-1 or DMBA induced tumorigene-
sis. Future studies using conditional deletion of both alle-
les will address the question of whether complete loss of
SAFB1 expression results in increased mammary gland
tumorigenesis.
Methods
Animal models
MMTV-Wnt-1 transgenic mice (a kind gift from Dr. Larry
Donehower, Baylor College of Medicine) and those that
carry a mutant allele of SAFB1 have been described previ-
ously [6,15]. Male Wnt-1 mice (on a mixed SJL and
C57BL/6 background) were crossed with SAFB1 hetero-
zygous females (on a mixed C57BL/6J and 129Sv back-
ground) to generate the three genotypes used in our study:
SAFB1+/+/Wnt-1, SAFB1+/-/Wnt-1, and SAFB1+/-. For
DMBA analysis we used mice on a BALB/c background. All
animals were maintained in a pathogen-free facility at
Baylor College of Medicine, and fed a diet of standard
food and water ad libitum. All procedures were approved
by the BCM Institutional Animal Care and Use Commit-
tee.
Genotyping and Immunoblotting
The genotypes were determined by isolating tail DNA and
performing PCR. Primers used to detect the intact SAFB1
gene (5'-TAT TAT CAT CTG CAT TCA CCA GTT G-3' and
5'-TCT GTG CTC CCA TCA TCT GTC TTC TTG-3') gener-
ate a 715 bp PCR product. Primers used to detect LacZ (5'-
CTG CTG ATG AAG CAG AAC AAC TTT A-3' and 5'-GAC
AGA TTT GAT CCA GCG ATA CAG-3') generate a PCR
product of 306 bp. Primers used to detect Wnt-1 transgene
(5'-GAA CTT GCT TCT CTT CTC ATA GCC-3' and 5'-CCA
CAC AGG CAT AGA GTG TCT GC-3') generate a 350 bp
PCR product.
To confirm decreased SAFB1 protein levels of hetero-
zygous mice compared to wild type mice, snap-frozen tes-
tes, spleen, lung, kidney, uterus and mammary gland
tissues from SAFB1+/+and SAFB1+/- mice were crushed,
lysed in 5% sodium dodecyl sulfate (SDS), and sonicated.
Proteins were resolved by SDS polyacrylamide gel electro-
phoresis and transferred to a nitrocellulose membrane.
After blocking (PBS and 0.1% Tween 20 (PBST) + 5%
milk), membranes were probed with SAFB1 [6] and β-
actin (Sigma) antibodies. Protein-antibody complexes
were detected using horseradish peroxidase-linked sec-
ondary anti-mouse or anti-rabbit (Amersham Bio-
sciences), and the signal was developed using enhanced
chemiluminescence (Pierce) according to manufacturer's
instructions. Bands were quantitated using FluorChem
8000 (Alpha Inotech Corp.) and averaged the percentages
of SAFB1 expression in all analyzed tissues of SAFB1+/-
mice with respect to the SAFB1+/+ mice
Tumorigenesis study
For DMBA induced tumorigenesis, 8 week old virgin
female BALB/c mice were treated with 1 mg/week DMBA
(Sigma-Aldrich Inc, St. Louis, MO), dissolved in cotton
seed oil (Sigma-Aldrich Inc, St. Louis, MO) by gavage for
6 consecutive weeks. Control mice received cotton seed
oil only.
After weaning (Wnt tumor), or one week after DMBA
treatment (DMBA tumor) mice were monitored 3 times/
week for tumor formation by visual inspection and palpa-
tion. Tumors were measured with a calliper and volume
was calculated according to the formula (W*W*L)/2,
where W is the width and L is the length. Mice where euth-
anized when tumor volume reached > 1000 mm3 or gen-
eral health conditions deteriorated due to unknown
reasons. All animals that did not develop palpable tumors
were harvested at the end of the study period (50–52
weeks after DMBA treatment). Necropsies were performed
to determine incidence of non-palpable tumors or blood
disorders. Mice were injected with 100 mg/kg BrdU 2 hr
prior to sacrifice for subsequent measurements of prolifer-
ation. At the time of sacrifice, tumors and lungs were
removed. Part of the tumors was used for paraffin-embed-
ding and the remaining part was frozen at -80°C. Blood
samples were obtained from some of the animals and
analyzed for hematological parameters. Control mice
without the Wnt-1 transgene of both groups SAFB1+/-
female and male mice were monitored for up to 18
months. In the Wnt-1 study, both breeding and non-
breeding males and only virgin females were used for data
collection.
Histological analysis
Lung and tumor cross-sections were fixed in fresh 4%
paraformaldehyde overnight, and stored in 70% ethanol
until embedding. Samples were paraffin embedded, sec-
tioned, and H&E stained using standard protocols, by the
Breast Center Pathology Core at BCM. For the immuno-
histochemical (IHC) staining, we have used rabbit anti-
caspase 3 antibody (Cell Signalling) to measure apoptosis
and BrdU In Situ detection kit II (BD Pharmingen) to ana-
lyze proliferation. In the Wnt study we have additionally
stained with anti-phosphorylated H3 (Upstate) to meas-
ure mitotic index of the tumors.
Three photographs from different areas of the tumors
were taken per each slide and the percentage of these
apoptotic and proliferations marker-positive cells was cal-
culated. Blood samples were taken from 17 DMBA treatedMolecular Cancer 2009, 8:15 http://www.molecular-cancer.com/content/8/1/15
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mice (7 SAFB1+/+, 8 SAFB1+/- and 2 control) by cardiac
puncture. Haematological analyses were carried out on
the Advia 120 (Bayer Diagnostics) automated hematology
analyzer, and blood smears were evaluated for abnormal-
ities.
Statistical Analysis
For all statistical tests, p ≤ 0.05 was considered statistically
significant. The time from birth (Wnt-1 tumors) or from
the first DMBA treatment to the time of tumor appearance
and death were subjected to Kaplan-Meier analysis.
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